Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets

With inflation readings, Fed decisions and energy costs all pulling at markets at once, defensive dividend stocks are suddenly back in focus for investors who care about stability as much as growth. This screener looks for larger US companies that combine income, moderate risk profiles and measured volatility at a time when many worry about what comes next. Ahead, you will see three stocks that appear better positioned against these crosswinds.

The three stocks highlighted next are just a starting sample. The full screen surfaced 11 more large-cap US dividend companies with equally compelling income and risk profiles that are not covered here. If you want to identify your own highest-conviction ideas, head straight to the US Large-Cap Defensive Dividend Stocks screener.

Abbott Laboratories (ABT)

Overview: Abbott Laboratories is a global healthcare company that develops and sells diagnostics, medical devices, nutrition products and established pharmaceuticals, which can give investors exposure to recurring healthcare demand and dividend income within a defensive large cap profile. Its mix of essential tests, chronic disease devices like glucose monitoring and everyday nutrition brands helps spread risk across different parts of the healthcare system.

Operations: Abbott generates most of its revenue from Medical Devices at about US$22.5b, followed by Diagnostic Products at roughly US$10.0b, Nutritional Products at around US$8.3b, Established Pharmaceutical at about US$5.8b, with a small contribution from Other activities.

Market Cap: US$187.5b

Income focused investors may want to pay attention to Abbott Laboratories because it combines a long established dividend, a multi segment healthcare portfolio and exposure to structural trends like aging populations and chronic disease. The company is leaning into areas such as cancer diagnostics, glucose monitoring and cardiovascular devices, which analysts link to higher margin potential. Its nutrition business behaves more like a consumer staple during inflation and energy cost spikes. At the same time, higher leverage, margin pressure from tariffs, commodities and pricing, and ongoing regulatory and litigation issues mean future earnings are not risk free. If you are looking for a defensive large cap that aims to balance stability with new product launches, Abbott is worth a closer look.

Abbott Laboratories is focusing on recurring healthcare demand, yet many investors still treat it as a simple dividend story. Study the 3 key rewards and 2 important warning signs that could reshape how you view its long term risk and return balance.

UnitedHealth Group (UNH)

Overview: UnitedHealth Group is a large US healthcare company that pairs a major health insurance business with a fast growing services platform, providing coverage, pharmacy benefits and care delivery to employers, governments and individuals in the US and abroad. That mix of recurring insurance premiums and fee based Optum services, combined with a long running dividend, is why it fits a defensive, income oriented dividend screen.

Operations: UnitedHealth Group generates most of its revenue from UnitedHealthcare at about US$346.5b, with Optum Rx contributing roughly US$155.2b, Optum Health about US$100.0b, Optum Insight around US$19.7b, and smaller negative adjustments from other segments.

Market Cap: US$356.5b

Investors looking at UnitedHealth Group today see a combination of scale, a dividend and diversified cash flow across insurance, pharmacy benefits and data driven care services at a time when inflation, rates and wage pressure are front of mind. Management is reshaping Medicare Advantage and expanding value based and home based care, which could affect margins and claims predictability as medical costs and labor rates move around. At the same time, the company is working through weaker recent margins, complex Medicare rule changes and higher funding sensitivity from its debt heavy balance sheet. Investors who want to explore a healthcare stock that aims to turn technology investments and Medicare changes into a more efficient, recurring earnings structure may want to study this company more closely.

UnitedHealth Group’s scale and services engine could be masking a very different earnings story than many assume. Scan the 3 key rewards and 1 important warning sign before the next round of Medicare changes quietly rewrites the script.

Bunge Global (BG)

Overview: Bunge Global is a large agribusiness and food company that processes oilseeds and grains and supplies essential ingredients to food, animal feed and biofuel customers worldwide. This links it directly to global demand for staple commodities and fits the defensive dividend theme of this screener.

Operations: Bunge Global generates most of its revenue from Soybean Processing and Refining at about US$44.3b and Grain Merchandising and Milling at roughly US$29.7b. It also receives additional contributions from Softseed Processing and Refining at around US$17.8b and Tropical Oils and Specialty Ingredients at about US$5.2b, as well as small amounts from Corporate and Other, partly offset by eliminations.

Market Cap: US$22.8b

Income focused investors looking at Bunge Global today get a mix of dividend income, exposure to essential food and feed flows and a business that can sometimes benefit when inflation, energy prices and trade frictions affect commodity markets. The company is focusing on higher value processing, renewable fuel driven vegetable oil demand and the Viterra merger, which together aim to strengthen margins and cash generation. Earnings remain sensitive to biofuel policy shifts, weather, trade routes and heavy capital spending. With a share price that screens at a steep discount to some intrinsic value estimates and a dividend whose cash flow cover is under scrutiny, Bunge Global may warrant a closer look if you want defensive leaning agribusiness exposure and are prepared for more commodity linked swings than a typical consumer staple.

Bunge Global’s valuation gap and dividend story may be only half the picture. Scan the 2 key rewards and 3 important warning signs (1 is major!) to see how its commodity swings, Viterra deal and cash generation could intersect in an unexpected way.

Seeking Fresh Alternatives Beyond Dividends

Markets move fast and the best breakout ideas rarely stay quiet for long. Tap into fresh momentum and under the radar opportunities before the crowd catches up, and consider acting promptly.

• Spot resilient income plays with strong balance sheets and steady momentum by running the 11 dividend fortresses while these higher yield opportunities are still flying under the radar.
• Hunt for potential future tech leaders by scanning the 29 AI small caps before attention and capital rotate toward these smaller AI stocks and the most attractive entry points become less available.
• Seek exposure to real assets by reviewing the curated 35 elite gold producer stocks while sentiment remains mixed and potential breakout producers may still be underpriced relative to their production profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com